Arkolith/Insider Trading/BCAX/Form 4

Mazumdar Claire

Chief Executive Officer, DirectorBicara Therapeutics Inc. (BCAX) · full profile →Form 4 · filed Jul 14, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$284K
Net Open-Market Flow
-$284K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 10, 2026Option exercise(M)10K$3.79$38K372K
Jul 10, 2026Sell(S)10K$28.42$283K362K
Jul 10, 2026Sell(S)28$29.68$831362K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 10, 2026Option exercise(M)10K—$0121K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000714) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML